2024
Mechanism of Negative Feedback Regulation of Oncogenic BCR-Signaling in Mature B-Cell Lymphoma
Sun R, Lee J, Robinson M, Kume K, Zhan C, Cheng Z, Cosgun K, Chan L, Leveille E, Kothari S, Katz S, Ma N, Vykunta V, Shy B, Hodson D, Marson A, Vaidehi N, Müschen M. Mechanism of Negative Feedback Regulation of Oncogenic BCR-Signaling in Mature B-Cell Lymphoma. Blood 2024, 144: 3003-3003. DOI: 10.1182/blood-2024-211693.Peer-Reviewed Original ResearchB-cell lymphomaGC B cellsB-cell lymphoma cellsB cellsBCR signalingGerminal centersProteolytic cleavageNK cellsLymphoma cellsMantle cell lymphoma xenograftsAggressive B-cell lymphomasMature B-cell lymphomasB-cell lymphoma subtypesGerminal center B cellsSpontaneous germinal centersGlobal phosphoproteomic studiesActivation marker CD69Aggressiveness of diseaseCD25 surface expressionMechanism of negative feedback regulationB cell autoimmunityFollicular dendritic cellsHuman germinal centerCa2+ oscillationsExpressed increased levels
2021
High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers
Zayac A, Landsburg D, Hughes M, Ayers E, Girton M, Hu M, Beckman A, Li S, Medeiros L, Kurt H, Sandoval-Sus J, Ansari-Lari M, Kothari S, Kress A, Xu M, Torka P, Sundaram S, Smith S, Naresh K, Karimi Y, Epperla N, Bond D, Evens A, Pandya K, Naik S, Kamdar M, Haverkos B, Karmali R, Oh T, Vose J, Nutsch H, Rubinstein P, Chaudhry A, Olszewski A. High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers. Blood 2021, 138: 455. DOI: 10.1182/blood-2021-144308.Peer-Reviewed Original ResearchInternational Prognostic IndexDA-EPOCHOverall survivalComplete responseB-cell lymphomaWorld Health OrganizationSpeakers bureauADC therapeuticsLactate dehydrogenaseCommon first-line regimensHigh serum lactate dehydrogenaseAdvisory board membersChimeric antigen receptor T cellsCentral nervous system involvementAntigen receptor T cellsGrade B-cell lymphomaAdvisory CommitteeAggressive B-cell lymphomasMYC extra copiesPoor performance statusOutcomes of patientsDe novo tumorsFirst-line regimensNervous system involvementGerminal center B-cell phenotype